SecBot SecBot

DCTH drug pipeline

DELCATH SYSTEMS, INC. · 1 rated drug
$19.87
−3.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±79.4%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved (FDA)
Time to marketAlready on the market. FDA-approved August 2023, currently generating commercial revenue.

HEPZATO KIT melphalan hydrochloride Updated Nov 11

What to watch

With no binary FDA catalyst ahead, the stock's near-term direction hinges on commercial execution: watch Q4 2026 earnings (expected early 2027) for continued HEPZATO KIT revenue growth and treatment center expansion. The Phase 2 breast cancer trial is an important long-term value driver but is unlikely to produce pivotal data within 12 months. The stock's 52-week high near $22.32 and strong institutional accumulation suggest the market is already pricing in the current growth trajectory.

Bull case
  • First-mover advantage: HEPZATO KIT is the only FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, a niche with no direct FDA-approved competitor.
  • Strong commercial momentum: Q3 2026 HEPZATO KIT revenue of $32.7M grew ~70% YoY, with full-year 2026 guidance raised to $115M-$117M, implying continued rapid adoption.
  • Expanding treatment network: 31+ active U.S. centers with a target of 36+ by year-end 2026, driving volume growth of at least 41% over 2025.
Bear case
  • Narrow approved indication: The current label is limited to unresectable hepatic-dominant metastatic uveal melanoma with less than 50% liver involvement, a relatively small patient population.
  • Procedure complexity: HEPZATO requires specialized interventional radiology infrastructure and trained staff, limiting the addressable treatment centers and creating a barrier to rapid expansion.
  • Safety profile: The FDA label carries a boxed warning for peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events, plus myelosuppression. The drug is only available through a restricted REMS program.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Aug 14, 2023HEPZATO KITApproval+79.4%+60.8%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
—Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaPhase 3Completed · results102May 18, 2023